With 0.97 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.84 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $5.05 whereas the lowest price it dropped to was $4.8. The 52-week range on SRTA shows that it touched its highest point at $6.02 and its lowest point at $2.35 during that stretch. It currently has a 1-year price target of $9.25. Beta for the stock currently stands at 1.98.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SRTA was up-trending over the past week, with a rise of 6.78%, but this was up by 2.44% over a month. Three-month performance surged to 14.81% while six-month performance rose 46.09%. The stock gained 18.59% in the past year, while it has gained 35.12% so far this year. A look at the trailing 12-month EPS for SRTA yields -0.25 with Next year EPS estimates of 0.25. For the next quarter, that number is 0.05. This implies an EPS growth rate of 129.87% for this year and 138.10% for next year.
Float and Shares Shorts:
At present, 86.05 million SRTA shares are outstanding with a float of 56.55 million shares on hand for trading. On 2025-10-31, short shares totaled 2.6 million, which was 301.99999 higher than short shares on 1759190400. In addition to Ms. Melissa M. Tomkiel J.D. as the firm’s Co- CEO, General Counsel & Director, Mr. William A. Heyburn serves as its Co- CEO, CFO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2021-12-31, SRTA reported revenue of $70801000.0 and operating income of -$4954000.0. Over the past year, revenue came in at $67.16M while operating income stood at -$32.26M. It generated -$3743000.0 net income for the quarter, which came to -$36.92M over the last twelve months. The EBITDA in the recently reported quarter was -$3255000.0 and diluted EPS was -$0.05. EBITDA for the full year was -$21.93M.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With SRTA analysts setting a high price target of 11.25 and a low target of 7.25, the average target price over the next 12 months is 9.25. Based on these targets, SRTA could surge 123.21% to reach the target high and rise by 43.85% to reach the target low. Reaching the average price target will result in a growth of 83.53% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.34008 being high and -$0.34984 being low. For SRTA, this leads to a yearly average estimate of -$0.34496. The surprise factor in the prior quarter was -$0.05. Based on analyst estimates, the high estimate for the next quarter is $0.01 and the low estimate is $0.01. The average estimate for the next quarter is thus $0.01.
